1313206-42-6

1313206-42-6 structure

Name: Polatuzumab vedotin
Chemical Name: Polatuzumab vedotin
CAS Number: 1313206-42-6
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Cell Cycle/DNA Damage Microtubule/Tubulin
Create Date: 2023-01-15 17:52:03
Modify Date: 2025-08-25 18:49:08
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1].

Name	Polatuzumab vedotin

Description	Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin
In Vivo	Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B‐cell lymphoma WSU‐DLCL2[2]. Animal Model: SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)[2] Dosage: 0.3, 1, 3, 6, 12 mg/kg Administration: I.v.; once Result: Showed dose-dependent tumour growth inhibition.
References	[1]. Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716. [2]. Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818.

No Any Chemical & Physical Properties